Name (Synonyms) | Correlation | |
---|---|---|
drug340 | BI 1569912 Wiki | 0.71 |
drug2884 | The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: Wiki | 0.71 |
drug2122 | Placebo Wiki | 0.04 |
Name (Synonyms) | Correlation | |
---|---|---|
D001997 | Bronchopulmonary Dysplasia NIH | 0.71 |
D008595 | Menorrhagia NIH | 0.71 |
D006929 | Hyperaldosteronism NIH | 0.71 |
D054559 | Hyperphosphatemia NIH | 0.71 |
D004314 | Down Syndrome NIH | 0.71 |
D000309 | Adrenal Insufficiency NIH | 0.71 |
D007008 | Hypokalemia NIH | 0.71 |
D014552 | Urinary Tract Infections NIH | 0.50 |
D001289 | Attention Deficit Disorder with Hyperactivity NIH | 0.35 |
D006470 | Hemorrhage NIH | 0.35 |
D020141 | Hemostatic Disorders NIH | 0.19 |
D001778 | Blood Coagulation Disorders NIH | 0.19 |
D006973 | Hypertension NIH | 0.18 |
D004194 | Disease NIH | 0.12 |
D013577 | Syndrome NIH | 0.07 |
D003141 | Communicable Diseases NIH | 0.06 |
D007239 | Infection NIH | 0.04 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.03 |
D018352 | Coronavirus Infections NIH | 0.03 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0002905 | Hyperphosphatemia HPO | 0.71 |
HP:0002900 | Hypokalemia HPO | 0.71 |
HP:0000846 | Adrenal insufficiency HPO | 0.71 |
HP:0000132 | Menorrhagia HPO | 0.71 |
HP:0000859 | Hyperaldosteronism HPO | 0.71 |
HP:0007018 | Attention deficit hyperactivity disorder HPO | 0.35 |
HP:0001928 | Abnormality of coagulation HPO | 0.19 |
HP:0000822 | Hypertension HPO | 0.18 |
There are 2 clinical trials
The purpose of this study is to investigate the infectious etiology of Kawasaki disease (KD); a prospective household and case control study for Kawasaki disease will be done. The investigators will enroll Kawasaki disease cases who have at least five of the following manifestations: 1. fever for over 5 days 2. neck lymphadenopathy 3. lip fissure and/or strawberry tongue 4. skin rash 5. nonpurulent bulbar conjunctivitis 6. palm/sole erythema and induration followed by desquamation, or coronary artery aneurysm with less than 5 of the above manifestations (atypical Kawasaki disease) The KD cases will receive virological (virus isolation from the blood, throat swabs and rectal swabs or stool, gene chip for possible viruses from stored RNA and DNA), bacterial (blood, throat swabs and stool: bacterial culture and stored strain for further toxin or superantigen detection), and serological (Mycoplasma pneumoniae, Chlamydiae pneumoniae, ASLO, HHV6, EV71, peptide library approach for auto-antibody or pathogen-related antibody, stored serum for further workup) workup. Stored DNA from the blood will also be performed.
Description: The mean age of the 226 KD cases was 2.07 years, and the male to female ratio was 1.43 (133 boys to 93 girls). Their mean fever duration was 7.5 days with a mean peak temperature of 39.7°C. In addition to the typical symptoms of fever, neck lymphadenopathy, lip fissure and/or strawberry tongue, skin rash, nonpurulent bulbar conjunctivitis, palm/sole erythema, and induration followed by periungual desquamation, these KD cases also exhibited cough (69%), rhinorrhea (58%), and diarrhea (45%). Cases of KD had a significantly higher positive rate of viral isolation in comparison with the control group (7.5% vs. 2.2%, p = 0.02). Compared with the control group, cases of KD were more likely to have overall positive rates of viral PCR (50.4% vs. 16.4%, p < 0.001) and for various viruses including enterovirus (16.8% vs. 4.4%, p < 0.001), adenovirus (8.0% vs. 1.8%, p = 0.007), human rhinovirus (26.5% vs. 9.7%, p < 0.001), and coronavirus (7.1% vs. 0.9%, p = 0.003).
Measure: Viral infections associated with Kawasaki disease Time: 2014/3The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.